Our Technology

Learn about

Our Prognostic Tests

PredictImmune is developing a pioneering suite of prognostic tools to guide treatment choice and improve patient outcomes in immune-mediated diseases. Our first product, PredictSURE® IBD stratifies patients with IBD (both Crohn’s disease and ulcerative colitis) based on likely long-term outcomes.

Our core technology is based on over 15 years of world-leading research in Professor Ken Smith’s laboratory in the Department of Medicine, at the University of Cambridge.
The test identifies patients with an underlying condition known as T-cell exhaustion based on the expression of 15 informative biomarkers.

T-cell Exhaustion and its Role in Prognosis

T-cells and immune-mediated inflammatory disease

PredictImmune’s core technology utilises biomarkers that identify a natural immunological state known as exhaustion. Exhaustion is a state of cellular dysfunction which reduces the ability of activated immune cells called T-cells to fight against chronic infection.

In exhaustion, prolonged killer T-cell activation results in a downregulation of their ability to kill target cells, to produce inflammatory signals and to divide and produce new T-cells.

T-cells also play an important role in “self-reactive” responses, causing inflammation and damage to healthy tissue central to immune-mediated inflammatory diseases. In this context, T-cell exhaustion can be helpful and has been linked to better long-term outcomes in immune diseases such as inflammatory bowel disease.

Prognostic testing for immune-mediated inflammatory disease

This link between T-cell exhaustion and inflammatory disease outcome is the basis of our risk-stratifying prognostic test in inflammatory bowel disease. Our technology is based on a whole blood biomarker of T-cell exhaustion that identifies patients with lower levels of exhaustion who are at risk of early and frequent relapses. This allows clinicians to personalise treatment options, with the aim of preventing long term tissue damage and improving outcomes.